GlassScriptPhysician profile
Mukeshchandra Patel
NPI 1639106198
$11,345.94
in general payments reported to CMS, 2019-2025
40 companies · $3,127 in 2025
The $3,127 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $964 · 2021: $908 · 2022: $1,715 · 2023: $2,154 · 2024: $1,461 · 2025: $3,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,191 · Travel and Lodging: $1,453 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,190.82 |
| Travel and Lodging | $1,452.85 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,269.54 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan, Mycarelink |
| Astrazeneca Pharmaceuticals LP | $1,299.19 | 2019-2025 | Farxiga, Brilinta, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $726.06 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $576.98 | 2021-2025 | Verquvo, Recarbrio, Zerbaxa |
| Bayer Healthcare Pharmaceuticals INC. | $562.65 | 2022-2025 | |
| Glaxosmithkline, LLC. | $476.69 | 2019-2025 | Trelegy Ellipta |
| Abbott Laboratories | $449.50 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3, Diamondback Coronary |
| Novartis Pharmaceuticals Corporation | $403.31 | 2020-2025 | |
| Medtronic Vascular, INC. | $385.81 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $380.42 | 2019-2024 | Xarelto |
| Mylan Specialty L.P. | $348.99 | 2019-2024 | Yupelri |
| Pfizer INC. | $327.62 | 2019-2025 | |
| Novo Nordisk INC | $257.48 | 2019-2025 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $254.37 | 2022-2025 | Lux-Dx Insertable Cardiac Monitor, General - Brady, Resonate El Icd Vr |
| Actelion Pharmaceuticals US, INC. | $185.40 | 2019-2024 | Uptravi |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $152.02 | 2019-2024 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $133.90 | 2020-2024 | Nexletol |
| United Therapeutics Corporation | $128.90 | 2020-2021 | |
| Biotronik INC. | $102.88 | 2020-2023 | Biomonitor |
| Eisai INC. | $96.78 | 2019-2022 | |
| Philips North America LLC | $96.70 | 2019-2025 | Respiratory |
| Sanofi-Aventis U.S. LLC | $89.78 | 2019-2021 | |
| Corcept Therapeutics | $75.32 | 2025 | Korlym |
| Dexcom, INC. | $67.38 | 2023-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $63.60 | 2025 | Rexulti |
| Lexicon Pharmaceuticals, INC. | $62.46 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $61.59 | 2022-2024 | |
| Abiomed | $47.00 | 2020-2025 | |
| Amgen INC. | $41.23 | 2022-2025 | Krystexxa |
| Advanced Respiratory, INC | $31.71 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $22.42 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $21.51 | 2024 | Arcalyst |
| Cordis US Corp. | $20.75 | 2025 | Mynx Control Venous |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.45 | 2024 | Xifaxan |
| Cequr Corporation | $20.20 | 2023 | Cequr Simplicity |
| Chiesi USA, INC. | $20.18 | 2022 | |
| Baxter Healthcare | $19.89 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Arbor Pharmaceuticals, INC. | $19.50 | 2022 | |
| Gilead Sciences, INC. | $13.61 | 2019 | |
| Lilly USA, LLC | $12.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukeshchandra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.